- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378623
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli (PARADOX)
PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, double-blinded, placebo-controlled, randomized controlled trial (RCT).
400 patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. The majority of patients will begin intervention with Apixaban or placebo at the time of cardiac device placement (n approximately 300), and at least a quarter of the randomized patients (n ≥100) will include preexisting CIED (≥6 months) in place. Each patient will undergo a baseline MRI and a comprehensive cognitive screening examination. Repeat MRI and cognitive assessment will be performed at a follow-up period of two years from date of randomization (or less if clinical stroke/TIA occurs prior to this follow-up period). All subjects will receive a phone call at 6 months, 12 months, and 18 months post-randomization to assess for endpoints and adverse events, as well as changes in clinical status, medications, and to assess study medication compliance.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- A clinical indication for a trans venous pacemaker, ICD, or CRT device, or presence of a pre-existing endovascular CIED
- Presence of a PFO (regardless of shunt direction) confirmed with trans-esophageal or trans-thoracic echocardiography with color flow Doppler and/or agitated saline
- Absence of any contraindication for anticoagulation
- Absence of a clinical indication for systemic anticoagulation
- Ability to give informed consent for the trial
- Able to undergo head MRI and consent for MRI study to be performed in presence of CIED
Exclusion:
- Patients with a survival expectancy of less than one year
- Patients who require systemic anticoagulation for any established clinical indication (excluding the presence of PFO with CIED)
- Patients with an atrial or ventricular septal defect that is hemodynamically significant and requires repair as suggested by the ACC/AHA 2008 guidelines on evaluation and treatment of adult congenital heart diseases
- Absence of a CIED or no clinical indication for a trans venous CIED
- Contraindication to undergoing an MRI
- Patients with an active infection that cannot be treated successfully prior to randomization
- Women who are pregnant or breastfeeding, or women of child-bearing potential who do not wish to use an effective method of birth control during the course of study in a manner such that the risk of failure is minimized
- Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)
- Known sensitivity to any of the active substances or their excipients to be administered during dosing with study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Apixaban
Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5
mg/dL).
Planned treatment duration is 2 years
|
Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo.
The randomization will be performed by a computer generated block randomization protocol.
Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Other Names:
|
Placebo Comparator: Placebo
Control group: Matched placebo by mouth two times daily in addition to usual medical therapy.
Planned treatment duration is 2 years.
|
Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo.
The randomization will be performed by a computer generated block randomization protocol.
Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase in number of new brain lesions detected on MRI ≥3 mm in size at 2 years post-baseline MRI (or earlier if premature termination of study follow-up).
Time Frame: 2 years
|
The primary objective of this study is to determine whether medical therapy with apixaban lowers the rate of new MRI cerebral lesions compared to placebo in pacemaker, defibrillator, and resynchronization device therapy recipients with a PFO
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Samuel Asirvatham, MD, Mayo Clinic
- Principal Investigator: Christopher DeSimone, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Congenital Abnormalities
- Embolism and Thrombosis
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Heart Septal Defects, Atrial
- Heart Septal Defects
- Thromboembolism
- Foramen Ovale, Patent
- Embolism, Paradoxical
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Apixaban
Other Study ID Numbers
- 13-008633
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patent Foramen Ovale
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
Carag AGCompleted
-
W.L.Gore & AssociatesRecruitingStroke | PFO - Patent Foramen OvaleUnited States
-
Wolfson Medical CenterUnknownClosure of the Foramen Ovale and Ductus ArteriosusIsrael
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruitingMigraine | PFO - Patent Foramen OvaleChina
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of OregonEnrolling by invitationPatent Foramen OvaleUnited States
-
Lifetech Scientific (Shenzhen) Co., Ltd.CompletedPatent Foramen OvaleIreland, Germany
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
Clinical Trials on Apixaban
-
PfizerBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingCancer-associated ThrombosisFrance, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Portola PharmaceuticalsCompleted
-
Baim Institute for Clinical ResearchBristol-Myers SquibbCompletedAtrial FibrillationUnited States
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
-
Universitaire Ziekenhuizen KU LeuvenRecruitingAnticoagulation | Short Bowel SyndromeBelgium
-
Artivion Inc.Duke Clinical Research InstituteTerminatedAortic Valve Stenosis | Aortic Valve Disease | Aortic Valve FailureUnited States